GSK plc高管披露在执行储蓄计划账户中取得ADS
6-K - GSK plc (0001131399) (Filer)
GSK plc提交Form 6-K，披露美国总裁 Maya Martinez-Davis 在其 GSK Executive Supplemental Savings Plan 账户中取得名义美国存托股份（ADS）。交易于10月22日在纽约证券交易所进行，价格为每股51.2100美元，数量为9.324股。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the ‘Company’)
Transaction notification
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) |
||
|
a) |
Name |
Maya Martinez-Davis |
|
|
b) |
Position/status |
President, US |
|
|
c) |
Initial notification/ amendment |
Initial notification |
|
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
GSK plc |
|
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||
|
a) |
Description of the financial instrument |
American Depositary Shares (‘ADS’) ISIN: US37733W2044 |
|
|
b) |
Nature of the transaction |
Acquisition of notional ADS within Ms Martinez-Davis’s GSK Executive Supplemental Savings Plan account |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
$51.2100 |
9.324 |
||
|
d) |
Aggregated information |
N/A (single transaction) |
|
|
Aggregated volume Price |
|||
|
e) |
Date of the transaction |
2026-10-22 |
|
|
f) |
Place of the transaction |
New York Stock Exchange (XNYS) |
|
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
|
GSK plc |
|
|
(Registrant) |
|
|
Date: October 26, 2026 |
|
|
By:/s/ VICTORIA WHYTE -------------------------- |
|
|
Victoria Whyte |
|
|
Authorised Signatory for and on |
|
|
behalf of GSK plc |
来源：SEC EDGAR · 本站存档